Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Clinical Research
You have accessRestricted Access

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial

Sharon M. Moe, Safa Abdalla, Glenn M. Chertow, Patrick S. Parfrey, Geoffrey A. Block, Ricardo Correa-Rotter, Jürgen Floege, Charles A. Herzog, Gerard M. London, Kenneth W. Mahaffey, David C. Wheeler, Bastian Dehmel, William G. Goodman and Tilman B. Drüeke
JASN June 2015, 26 (6) 1466-1475; DOI: https://doi.org/10.1681/ASN.2014040414
Sharon M. Moe
*Indiana University School of Medicine and Roudebush Veterans Administration Medical Center, Indianapolis, Indiana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Safa Abdalla
†Stanford University School of Medicine, Palo Alto, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn M. Chertow
†Stanford University School of Medicine, Palo Alto, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick S. Parfrey
‡Health Sciences Center, St. John’s, Newfoundland, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey A. Block
§Denver Nephrology, Denver, Colorado;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Correa-Rotter
‖Salvador Zubirán National Institute of Medical Sciences and Nutrition, Mexico City, Mexico;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Floege
¶University Hospital RWTH Aachen, Aachen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles A. Herzog
**University of Minnesota, Minneapolis, Minnesota;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard M. London
††Manhès Hospital, Paris, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth W. Mahaffey
†Stanford University School of Medicine, Palo Alto, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Wheeler
‡‡University College London, London, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bastian Dehmel
§§Amgen Inc., Thousand Oaks, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William G. Goodman
§§Amgen Inc., Thousand Oaks, California; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tilman B. Drüeke
‖‖French Institute of Health and Medical Research (INSERM) Unit 1088, Faculty of Medicine/Pharmacy, University of Picardie, Amiens, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Fractures are frequent in patients receiving hemodialysis. We tested the hypothesis that cinacalcet would reduce the rate of clinical fractures in patients receiving hemodialysis using data from the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events trial, a placebo-controlled trial that randomized 3883 hemodialysis patients with secondary hyperparathyroidism to receive cinacalcet or placebo for ≤64 months. This study was a prespecified secondary analysis of the trial whose primary end point was all-cause mortality and non-fatal cardiovascular events, and one of the secondary end points was first clinical fracture event. Clinical fractures were observed in 255 of 1935 (13.2%) patients randomized to placebo and 238 of 1948 (12.2%) patients randomized to cinacalcet. In an unadjusted intention-to-treat analysis, the relative hazard for fracture (cinacalcet versus placebo) was 0.89 (95% confidence interval [95% CI], 0.75 to 1.07). After adjustment for baseline characteristics and multiple fractures, the relative hazard was 0.83 (95% CI, 0.72 to 0.98). Using a prespecified lag-censoring analysis (a measure of actual drug exposure), the relative hazard for fracture was 0.72 (95% CI, 0.58 to 0.90). When participants were censored at the time of cointerventions (parathyroidectomy, transplant, or provision of commercial cinacalcet), the relative hazard was 0.71 (95% CI, 0.58 to 0.87). Fracture rates were higher in older compared with younger patients and the effect of cinacalcet appeared more pronounced in older patients. In conclusion, using an unadjusted intention-to-treat analysis, cinacalcet did not reduce the rate of clinical fracture. However, when accounting for differences in baseline characteristics, multiple fractures, and/or events prompting discontinuation of study drug, cinacalcet reduced the rate of clinical fracture by 16%–29%.

  • CKD
  • hemodialysis
  • hyperparathyroidism
  • renal
  • osteodystrophy

Patients with end stage renal disease (ESRD) on dialysis have increased risk of fractures compared with the general population.1 Fracture incidence rates vary by geographic region, although rates are consistently higher in patients with CKD than matched controls from the same country.2–6 Depending on the study, 10%–52% of patients receiving dialysis have experienced one or more fractures (reviewed in Kaji et al.2 and Kidney Disease Improving Global Outcomes7). In nondialysis populations, secondary analyses of fracture studies show increased rates in patients with eGFRs<60 ml/min per 1.73 m2.8,9 Risk factors associated with fractures in patients with CKD include older age, female sex, lower serum albumin, prior kidney transplantation, peripheral vascular disease, muscle weakness, falls, and the administration of psychoactive medications.2,3,10–14 Thus, abnormalities of bone in terms of both quality and quantity, variable biochemical abnormalities, and multiple comorbid conditions are likely to contribute to the pathogenesis of fractures in ESRD. The complexity and nature of CKD-mineral and bone disorder (MBD) may also render conventional therapy for osteoporosis and osteopenia ineffective or possibly harmful in CKD or ESRD.

Secondary hyperparathyroidism is known to be associated with renal osteodystrophy. However, it is unclear whether the incidence of fractures in patients receiving dialysis has decreased in recent years despite active treatment of secondary hyperparathyroidism.15–18 Most previous studies of fracture in CKD and ESRD were cross-sectional or had limited follow-up, and/or fracture assessment was made from claims data rather than prospectively collected or adjudicated. Importantly, despite the availability and widespread use of phosphate binders and vitamin D sterols, no randomized controlled trials evaluated whether any drug or other therapeutic strategies (e.g., parathyroidectomy) lowered the risk of fracture in CKD and/or ESRD.

The objectives of this analysis were to determine fracture sites, frequency of and risk factors for clinical fracture events, and the effect of cinacalcet on clinical fracture rates in patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism using data from the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.19 We hypothesized that secondary hyperparathyroidism is a major cause of bone loss and increased bone fragility, and therefore treatment with cinacalcet would reduce clinical fractures.

Results

Baseline Characteristics

The baseline characteristics of the population,20 trial design,21 disposition of trial participants (Consolidated Standards of Reporting Trials diagram), primary results,22 and effect on the risk of severe unremitting hyperparathyroidism23 were previously published. The trial population was diverse in terms of age, sex, race/ethnicity, and comorbidity; the median dialysis vintage was 45.3 months.22 Baseline demographic, medication, and laboratory values pertinent to fracture risk are listed in Table 1. Using an unadjusted intention-to-treat analysis, the effect of cinacalcet on the primary composite end point, composed of all-cause mortality or first nonfatal cardiovascular event (myocardial infarction, hospitalization for unstable angina, heart failure, or peripheral vascular event), was not statistically significant (relative hazard, 0.93; 95% confidence interval [95% CI], 0.85 to 1.02).24

View this table:
  • View inline
  • View popup
Table 1.

Baseline demographics, medical history, medication use, and laboratory values for the EVOLVE study participants

Fracture Events during the Study

Radiographic imaging was not routinely performed; thus, all fracture events were reported by study sites and thus should be considered clinical fractures. During the trial, 667 fractures were reported; 622 (93.7%) were adjudicated as true fracture events by the Clinical Events Committee. There were 493 patients that experienced at least one confirmed fracture (255 of 1935 [13.2%] randomized to placebo and 238 of 1948 [12.2%] randomized to cinacalcet). Fifty-nine participants experienced two fractures (29 and 30 in the placebo and cinacalcet groups, respectively) and 29 experienced three or more fractures (14 and 15 in the placebo and cinacalcet groups, respectively).

Fracture Sites

More than one-half of fractures in both groups involved predominantly cortical bone at nonhip sites. Supplemental Table 1 shows the total number of fracture events by site and incidence rates stratified by age, sex, and race. Figure 1 shows the unadjusted incidence of fractures by site, age, and randomized treatment assignment. Vertebral fractures were recorded in only 1.2% of the total patient population, in a total of 51 fracture events, almost certainly an underestimate because screening radiographs were not performed.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Unadjusted fracture rates by site, age, and treatment group. Fractures are more common at nonhip cortical sites compared with the hip, and are more common in patients aged ≥65 years. Bar graphs represent the mean±SD.

Clinical Fracture Rates

Cumulative clinical fracture rates were 4.7 (95% CI, 4.2 to 5.3) and 4.3 (95% CI, 3.8 to 4.8) per 100 patient-years in the placebo and cinacalcet groups, respectively. As shown in Figure 1, clinical fracture rates in patients aged <65 years were virtually identical (3.8; 95% CI, 3.3 to 4.4) in both groups. However, among patients aged ≥65 years, clinical fracture rates were 8.6 (95% CI, 7.1 to 10.4) in the placebo group and 6.0 (95% CI, 4.8 to 7.3) in the cinacalcet group (P<0.01). Figure 2 shows the cumulative incidence plot of time to first fracture for patients aged <65 years and patients aged ≥65 years using an intention-to-treat analysis.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Cumulative incidence of fractures. Cumulative incidence of clinical fractures in patients aged <65 years (top) and aged ≥65 years (bottom). Patients randomized to cinacalcet are shown with the solid line, and patients randomized to placebo are shown with the dashed line.

Effect of Cinacalcet on First Clinical Fracture

Intention-to-Treat Analyses

As previously reported using an unadjusted intention-to-treat analysis,22 the effect of cinacalcet on clinical fracture was not statistically significant (relative hazard, 0.89; 95% CI, 0.75 to 1.07). Despite randomization, median age was higher in patients randomized to cinacalcet, as was the proportion of elderly patients.22 After adjustment for age and other baseline characteristics, including fracture-related risk factors (previous fracture, history of tobacco use, provision of hormone replacement therapy and proton pump inhibitors, along with bone-related laboratory values), the relative hazard was 0.84 (95% CI, 0.69 to 1.01; P=0.07) (Table 2). Older age, female sex, diabetes, history of stroke and previous fracture, and tobacco use were associated with an increased rate of fracture, as were higher baseline bone-specific alkaline phosphatase (BALP), higher baseline serum calcium, and higher and lower baseline plasma parathyroid hormone (PTH) (Table 2). Supplemental Figure 1 shows a Forest plot for first clinical fracture by prespecified baseline clinical characteristics, and Supplemental Figure 2 shows the same by cointerventions for CKD-MBD using the multivariable-adjusted intention-to-treat analyses.

View this table:
  • View inline
  • View popup
Table 2.

Multivariable Cox regression of the effect of cinacalcet on the occurrence of first clinical fracture, by intention-to-treat analysis

Lag-Censoring Analysis

As previously reported, more than two-thirds of patients in both groups discontinued the study drug for a variety of protocol-specified and nonprotocol-specified reasons.22 Moreover, kidney transplantation and provision of PTH-lowering therapies (parathyroidectomy and off-protocol use of cinacalcet) were more common in patients randomized to placebo. Using a prespecified lag-censoring analysis (censoring time >6 months after stopping the study drug), the relative hazard for fracture was 0.72 (95% CI, 0.58 to 0.90; P=0.003) (Supplemental Table 2). Figure 3 shows effect modification by prespecified baseline clinical characteristics, and Figure 4 shows effect modification by cointerventions for CKD-MBD. Using the lag-censoring approach, the relative benefit of cinacalcet (or the relative harm of placebo plus conventional therapy) was more pronounced in patients treated with calcium-based phosphate binders (relative hazard, 0.55; 95% CI, 0.40 to 0.74; P=0.01) than in patients not treated, or treated with other, noncalcium-based phosphate binders (relative hazard, 0.98; 95% CI, 0.72 to 1.35). The relative benefit of cinacalcet appeared to be more pronounced among patients with baseline dialysate calcium ≥3.0 mEq/L, although the interaction (treatment group×dialysate calcium) was not significant (P=0.15).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Forest plot of treatment effect of cinacalcet on clinical fracture rate by prespecified baseline characteristics using lag-censoring analysis. HR, hazard ratio.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Forest plot of treatment effect of cinacalcet on clinical fracture rates by concomitant medications using lag-censoring analyses. HR, hazard ratio.

Censoring at Cointerventions

When we censored at time of the cointerventions of parathyroidectomy, kidney transplant, or provision of commercial cinacalcet, the relative hazard of fracture was 0.71 (95% CI, 0.58 to 0.87, P=0.001) (Supplemental Table 3).

Effect of Cinacalcet on Cumulative Clinical Fractures

When considering the risk of all clinical fractures (first plus subsequent) during the study, the unadjusted and multivariable-adjusted relative hazards (cinacalcet versus placebo) were 0.89 (95% CI, 0.76 to 1.05; P=0.16) and 0.83 (95% CI, 0.72 to 0.98; P=0.02). Using the lag-censoring approach, the relative hazard was 0.77 (95% CI, 0.63 to 0.94; P=0.01) (Supplemental Table 4).

Effect of Cinacalcet on Clinical Fractures in Older Versus Younger Patients

The adjusted relative hazards for clinical fractures by intention to treat were 0.92 (95% CI, 0.73 to 1.16) in patients aged <65 years and 0.69 (95% CI, 0.49 to 0.95) in patients aged ≥65 years (P value for treatment by age [continuous] interaction, P=0.06). Figure 3 shows unadjusted relative hazards using the lag-censoring approach; corresponding adjusted relative hazards were 0.79 (95% CI, 0.58 to 0.90) and 0.60 (95% CI, 0.41 to 0.88), with a corresponding interaction P=0.28.

Discussion

In the EVOLVE trial, we compared the relative safety and efficacy of cinacalcet and placebo along with conventional therapy for secondary hyperparathyroidism (typically phosphate binders and vitamin D sterols). The primary composite end point of the trial was all-cause mortality and nonfatal cardiovascular events; however, clinical fracture was a key secondary outcome, and reported fracture events were adjudicated along with major cardiovascular end points. Because we did not screen for fractures at baseline or at any fixed intervals or routinely perform imaging analysis to assess for vertebral fractures that are often asymptomatic,25 we almost certainly ascertained just a small fraction of all fractures that occurred during the trial. Moreover, the trial was powered for its adjudicated cardiovascular composite end point. Had our assumptions held, we would have had relatively low power to detect a clinically meaningful difference in all clinical fractures. Power was further reduced by very high rates of discontinuation of the study drug in both groups (actually higher in the placebo group), high rates of kidney transplantation in younger patients, and differential application of parathyroidectomy and commercial (off-protocol) cinacalcet in patients randomized to placebo compared with cinacalcet, as previously detailed.22 Despite factors reducing the power to detect a difference, the results in this secondary analysis were consistent across unadjusted, multivariable-adjusted, lag-censoring, and PTH-lowering event–censoring analyses, with point estimates of the rate reduction ranging from 16% to 29% in patients randomized to cinacalcet when differences in baseline characteristics (principally in age) were accounted for. These findings were nominally significant for the adjusted intention-to-treat analysis of cumulative fractures, and for both lag-censoring analyses (time to first fracture, and cumulative fractures).

The incidence of clinical fractures in this study was >4% per year. Two cross-sectional studies in dialysis patients found that 21% of patients in each patient population had prevalent vertebral fractures.26,27 The clinical fracture rates observed in the EVOLVE trial were slightly higher than in analyses from the prospective observational Dialysis Outcomes and Practice Patterns Study (DOPPS), in which the reported incidence was 2.6% per year when reported in 2006,3 and was 3% in a more recent DOPPS III report with a median follow-up of only 1.6 years.4 Readers should be reminded that patients enrolled in the EVOLVE trial were of longer dialysis vintage, and had more severe secondary hyperparathyroidism than the general hemodialysis population, perhaps explaining these differences. In this study, and in both of these DOPPS observational studies,3,28 fractures increased in older age groups. Fracture rates were much higher in older compared with younger patients, as virtually all other studies in the general population and CKD and ESRD populations have shown. The effect of cinacalcet appeared to be more pronounced in older patients. Although effect modification by age (the treatment×age interaction) was not statistically significant, the power to detect interventions with a relatively small number of events and a modest overall treatment effect is quite low. This observation could be explained by one of several factors: a true difference in the treatment effect, bias introduced by differential application of cointerventions (including kidney transplantation, parathyroidectomy, and provision of commercial cinacalcet), differential susceptibility to the effects of secondary hyperparathyroidism for which cinacalcet is prescribed, or lower event rates in younger patients, reducing statistical power. Given the high mortality, increased hospitalization rates, and costs associated with fractures,3,28–30 our study suggests that a reduction in fractures could have important personal health and societal financial benefits.

Given the mechanism of action of cinacalcet to reduce PTH release, it is probable that improvements in secondary hyperparathyroidism led to the observed effects on clinical fracture rates. This is further supported by the association between baseline increased BALP (indicating higher bone turnover) and fracture. The reduction in clinical fractures observed with cinacalcet treatment in this study was similar to that observed in a case control study of surgical parathyroidectomy in the United States that demonstrated a 32% reduction in subsequent hip fractures.31 The importance of PTH as a biomarker of abnormal bone is controversial.32,33 Cohort studies have shown an increased risk of fracture associated with low PTH12,29,30 or very high PTH.3,12,30,34 Some studies have found no significant relation to PTH.35,36 A meta-analysis suggested a direct effect of PTH.37 These apparently conflicting results may be attributable to the relative short t1/2 and normal oscillatory release of PTH such that a single value may not predict future outcomes. The results of this study evaluating the effect of cinacalcet, which reduces PTH,38 on reducing fracture rates supports an important role of PTH in the pathogenesis of fractures in patients with CKD.

This study demonstrated that nonhip cortical fractures were more common than hip fractures, although we did not search for radiographic evidence of asymptomatic spine fractures. We therefore cannot assume that cinacalcet exerts a similar effect on predominately cancellous bone sites such as the spine. Hyperparathyroidism predominately reduces cortical bone area39,40 and measures of cortical bone by dual x-ray absorptiometry or computed tomography are more predictive of fractures than other sites.41,42 In humans with secondary hyperparathyroidism, parathyroidectomy improves bone mineralization, reduces osteoclast bone resorption, enhances osteoblast bone formation, and leads to osteocytic death (thereby improving osteocytic osteolysis).43,44 In a uremic rat model with secondary hyperparathyroidism, treatment with a calcimimetic agent reduced osteitis fibrosa cystica, increased cortical bone mineral density, and corrected the CKD-induced loss of diaphyseal stiffness.45 In a different rat model of CKD, elevated PTH led to increased cortical porosity and increased fragility assessed by three-point bending studies.46 However, even in the absence of PTH, there were cortical bone abnormalities and fragility due to altered collagen crosslinking in CKD rats.47 Our trial did not utilize bone imaging or bone biopsy; thus, abnormalities of bone quality and the mechanism(s) of the observed effects of cinacalcet cannot be definitely determined. However, the results of this study, previous imaging studies, and experimental studies in animals are compatible with the construct that cortical bone may be preferentially altered in CKD/ESRD.

The strengths of these analyses include a randomized design, relatively large sample size, continued follow-up throughout the trial in 95% of participants, diversity (in age, sex, race/ethnicity, and clinical features of ESRD), breadth of comorbidity, laboratory data available at study entry, and most importantly, adjudication of clinical fracture end points by a trained Clinical Events Committee blinded to treatment assignment and other clinical features such as laboratory data. There are also several important limitations. By design, only patient-reported clinical fractures were identified; by not screening for asymptomatic fractures, we probably ascertained a small fraction of the fractures sustained by patients during the trial. We did not distinguish traumatic from atraumatic fractures and falls are a major determinant of fractures.13 Unfortunately, we did not collect data on muscle strength, falls, or physical activity in the EVOLVE trial. Although we accounted for the use of selected concomitant medications (phosphate binders, vitamin D sterols, and several other drugs prescribed at baseline), it is possible that participants took other medications at baseline or throughout the trial that might have made clinical fractures more or less likely. A large number of participants stopped taking cinacalcet for both protocol-specified and nonspecified reasons. In addition, it is highly likely that the observed treatment effect was attenuated by reduced adherence to, and “crossover” of, treatment and was further confounded by the effects of kidney transplantation and parathyroidectomy. Finally, the relatively small sample size may have precluded our ability to detect significant interactions between cinacalcet use and age or other covariates.

In summary, an unadjusted intention-to-treat analysis did not show a significantly reduced risk of clinical fracture in the group randomized to cinacalcet. However, when accounting for differences in baseline characteristics, multiple fractures, and/or events prompting discontinuation of the study drug, cinacalcet reduced the rate of clinical fracture by 16%–29%.

Concise Methods

Study Population and Design

In the EVOLVE trial, 3883 patients with secondary hyperparathyroidism receiving hemodialysis were randomized 1:1 to receive either cinacalcet (Sensipar; Amgen Inc) or placebo in addition to conventional therapies for CKD-MBD (i.e., instructions for dietary phosphorus restriction, phosphate binders, and vitamin D sterols).48 Eligible participants were on hemodialysis three times per week with plasma PTH concentrations ≥300 pg/ml (31.8 pmol/L), serum calcium phosphate product ≥45 mg2/dl2 (3.63 mmol2/L2), and serum calcium ≥8.4 mg/dl (2.1 mmol/L). The dose of the study drug was titrated once every 4 weeks during the first 20 weeks and every 8 weeks during the subsequent follow-up period (from a starting dose of 30 mg to a maximum dose of 180 mg daily), depending on blood levels of PTH and calcium. The dialysis prescription, other medical procedures, and doses of phosphate binders, vitamin D sterols, calcium supplements, and other medications were administered at the discretion of the treating physicians. Rates of withdrawal from cinacalcet, often related to gastrointestinal symptoms, were high; crossover from placebo to commercially available cinacalcet also reduced the trial’s power to detect a statistically significant result.22 The trial was led by an academic executive committee and was sponsored by Amgen Inc. Ethics committee approval was obtained at all participating sites; all patients gave informed consent. The EVOLVE trial is registered with ClinicalTrials.gov (NCT00345839).

Clinical Fracture Events

An independent Clinical Events Committee adjudicated all primary and secondary end points.22 Clinical fracture was a prespecified key secondary end point. Clinical fractures were ascertained at each visit by study personnel. Furthermore, all adverse events were screened for all components of the primary and secondary end points, such that clinical fractures that might have occurred in conjunction with other events were submitted for adjudication. Routine radiographic imaging was not performed to detect asymptomatic fractures. For the purpose of our analyses, fracture events were categorized as clinical vertebral and nonvertebral fractures, the latter being further subdivided into hip fractures (femur and intertrochanteric/subtrochanteric), nonhip predominantly cortical fractures (upper or lower extremities, ribs, or pelvis), and other nonvertebral fractures.

Biochemical Determinations

Biochemical markers of CKD-MBD including plasma intact PTH (normal range, 11–72 pg/ml) and serum concentrations of total calcium (8.3–10.6 mg/dl), phosphorus (2.2–5.1 mg/dl), 25-hydroxy vitamin D (11–72 ng/ml), and BALP (2.9–22.6 ng/ml) were analyzed at a central laboratory.

Sample Size Determination

Although the trial’s sample size was determined based on assumptions surrounding the primary composite end point (time to death, nonfatal myocardial infarction, hospitalization for unstable angina, heart failure, or peripheral vascular event), we prospectively calculated the power to detect differences in fracture rates based on the following assumptions: fracture rate of 4% per year in the placebo group, 1.5-year enrollment period, 4-year total study duration, lost to follow-up rate of 1% per year, a “drop-out” (withdrawal from treatment) rate of 10% per year in the cinacalcet group, and a “drop-in” (use of commercial cinacalcet) rate of 10% in the placebo group. Based on 3800 patients enrolled, we calculated the power to be approximately 60% to detect a 30% effect size using a two-sided α=0.044.

Statistical Analyses

The primary analysis for the effect of cinacalcet was conducted using the intention-to-treat principle. Prespecified secondary analyses included a multivariable proportional hazards (Cox) regression analysis adjusting for baseline characteristics, including age, sex, race (white, black, or other), geographic region, history of diabetes mellitus, history of cardiovascular diseases, and other variables known to be related to fracture in the general population (previous fracture, smoking, or use of hormone replacement therapy). Further covariates were selected by a process of backward elimination. Additional prespecified secondary analyses included a lag-censoring analysis, in which follow-up time >6 months after discontinuation of the study drug was censored, and a prespecified analysis censoring at cointerventions of parathyroidectomy, transplantation, and administration of commercial cinacalcet in the placebo arm.22 We used fractional polynomial regression to examine the association of baseline PTH with fractures.49 To examine the effect of cinacalcet on serial clinical fracture events, we utilized the Prentice–Williams–Petersen extension of Cox regression. We tested for effect modification by age, sex, race, geographic region, dialysis vintage (time since initiation of dialysis), diabetes, and baseline PTH using multiplicative interaction terms. We also explored whether the effect of cinacalcet on clinical fractures was more or less pronounced with differences in the prescription (at baseline) of phosphate binders, vitamin D sterols, and dialysate calcium.

All inference tests were performed without adjusting for multiple comparisons. Because the effects of randomization to cinacalcet versus placebo on the primary composite end point did not reach statistical significance on an unadjusted log-rank test,22 comparisons yielding two-tailed P values<0.05 were deemed nominally significant. All statistical analyses were conducted at Stanford University using SAS 9.3 software (SAS Institute Inc., Cary, NC).

Disclosures

B.D. and W.G.G. are employees and stockholders of Amgen, Inc.

Acknowledgments

The authors thank the EVOLVE study trial investigators and the patients.

The authors acknowledge the following sources of grants, consulting fees/honoraria, speaking fees, stock options, or travel support relevant to this article: Abbott/Abbvie (to T.B.D., J.F., C.A.H., R.C.-R., and D.C.W.), Affymax (to C.A.H.), Amgen, Inc., (to S.A., G.A.B., G.M.C., T.B.D., J.F., C.A.H., G.M.L., K.W.M., S.M.M., P.S.P., R.C.-R., and D.C.W.; to note, no honoraria were received for writing or reviewing the manuscript), Ardelyx (to G.A.B. and G.M.C.), Baxter (to T.B.D.), Boehringer-Ingelheim (to J.F.), Chugai Pharmaceutical Co. (to T.B.D. and J.F.), CorMedix (to C.A.H.), Fibrogen (to C.A.H.), Fresenius Medical Care (to T.B.D., J.F., R.C.-R., and D.C.W.), Genzyme/Sanofi (to G.A.B., R.C.-R., T.B.D., J.F., G.M.L., S.M.M., and D.C.W.), Home Dialysis Plus (to G.A.B. and G.M.C.), Johnson & Johnson (to C.A.H. and K.W.M.), KAI Pharmaceuticals (to G.A.B., T.B.D., and S.M.M.), Keryx (to G.A.B., G.M.C., and C.A.H.), Kirin Brewery Company (Pharmaceutical Branch) (to T.B.D.), Lilly (to S.M.M.), Medtronic (to C.A.H.), Merck GmbH (to D.C.W. and C.A.H.), Mitsubishi (to G.A.B.), Novartis (to S.M.M.), Otsuka (to D.C.W.), Pfizer (to R.C.-R.), Reata Pharmaceuticals (to G.M.C. and R.C.-R.), Roche (to R.C.-R. and T.B.D.), Sandoz (to G.M.L.), Shield (to G.A.B.), Shire (to T.B.D. and G.M.L.), Theraclion (to T.B.D.), Vifor (to S.M.M. and D.C.W.), and ZS Pharma (to C.A.H.).

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2014040414/-/DCSupplemental.

  • Copyright © 2015 by the American Society of Nephrology

References

  1. ↵
    1. Nickolas TL,
    2. McMahon DJ,
    3. Shane E
    : Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17: 3223–3232, 2006pmid:17005938
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Kaji H,
    2. Suzuki M,
    3. Yano S,
    4. Sugimoto T,
    5. Chihara K,
    6. Hattori S,
    7. Sekita K
    : Risk factors for hip fracture in hemodialysis patients. Am J Nephrol 22: 325–331, 2002pmid:12169863
    OpenUrlCrossRefPubMed
  3. ↵
    1. Jadoul M,
    2. Albert JM,
    3. Akiba T,
    4. Akizawa T,
    5. Arab L,
    6. Bragg-Gresham JL,
    7. Mason N,
    8. Prutz KG,
    9. Young EW,
    10. Pisoni RL
    : Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 1358–1366, 2006pmid:16929251
    OpenUrlCrossRefPubMed
  4. ↵
    1. Tentori F,
    2. McCullough K,
    3. Kilpatrick RD,
    4. Bradbury BD,
    5. Robinson BM,
    6. Kerr PG,
    7. Pisoni RL
    : High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85: 166–173, 2014
    OpenUrlCrossRefPubMed
    1. Maravic M,
    2. Ostertag A,
    3. Torres PU,
    4. Cohen-Solal M
    : Incidence and risk factors for hip fractures in dialysis patients. Osteoporos Int 2013
  5. ↵
    1. Wakasugi M,
    2. Kazama JJ,
    3. Taniguchi M,
    4. Wada A,
    5. Iseki K,
    6. Tsubakihara Y,
    7. Narita I
    : Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31: 315–321, 2013pmid:23292163
    OpenUrlCrossRefPubMed
  6. ↵
    1. Kidney Disease Improving Global Outcomes
    : Clinical practice guidelines for the management of CKD-MBD. Kidney Int 76: S1–S130, 2009
    OpenUrl
  7. ↵
    1. Nickolas TL,
    2. Leonard MB,
    3. Shane E
    : Chronic kidney disease and bone fracture: A growing concern. Kidney Int 74: 721–731, 2008pmid:18563052
    OpenUrlCrossRefPubMed
  8. ↵
    1. Naylor KL,
    2. McArthur E,
    3. Leslie WD,
    4. Fraser LA,
    5. Jamal SA,
    6. Cadarette SM,
    7. Pouget JG,
    8. Lok CE,
    9. Hodsman AB,
    10. Adachi JD,
    11. Garg AX
    : The three-year incidence of fracture in chronic kidney disease [published online ahead of print January 15, 2014]. Kidney Int doi:10.1038/ki.2013.547
    OpenUrlCrossRef
  9. ↵
    1. Alem AM,
    2. Sherrard DJ,
    3. Gillen DL,
    4. Weiss NS,
    5. Beresford SA,
    6. Heckbert SR,
    7. Wong C,
    8. Stehman-Breen C
    : Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58: 396–399, 2000pmid:10886587
    OpenUrlCrossRefPubMed
    1. Nickolas TL,
    2. Cremers S,
    3. Zhang A,
    4. Thomas V,
    5. Stein E,
    6. Cohen A,
    7. Chauncey R,
    8. Nikkel L,
    9. Yin MT,
    10. Liu XS,
    11. Boutroy S,
    12. Staron RB,
    13. Leonard MB,
    14. McMahon DJ,
    15. Dworakowski E,
    16. Shane E
    : Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 22: 1560–1572, 2011pmid:21784896
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Iimori S,
    2. Mori Y,
    3. Akita W,
    4. Kuyama T,
    5. Takada S,
    6. Asai T,
    7. Kuwahara M,
    8. Sasaki S,
    9. Tsukamoto Y
    : Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients–a single-center cohort study. Nephrol Dial Transplant 27: 345–351, 2012
    OpenUrlCrossRefPubMed
  11. ↵
    1. Jamal SA,
    2. Leiter RE,
    3. Jassal V,
    4. Hamilton CJ,
    5. Bauer DC
    : Impaired muscle strength is associated with fractures in hemodialysis patients. Osteoporos Int 17: 1390–1397, 2006
    OpenUrlCrossRefPubMed
  12. ↵
    1. West SL,
    2. Jamal SA,
    3. Lok CE
    : Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant 27: 2384–2388, 2012
    OpenUrlCrossRefPubMed
  13. ↵
    1. Wagner J,
    2. Jhaveri KD,
    3. Rosen L,
    4. Sunday S,
    5. Mathew AT,
    6. Fishbane S
    : Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant 29: 146–151, 2014
    OpenUrlCrossRefPubMed
    1. Nair SS,
    2. Mitani AA,
    3. Goldstein BA,
    4. Chertow GM,
    5. Lowenberg DW,
    6. Winkelmayer WC
    : Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol 8: 1336–1342, 2013pmid:23660182
    OpenUrlAbstract/FREE Full Text
    1. Beaubrun AC,
    2. Kilpatrick RD,
    3. Freburger JK,
    4. Bradbury BD,
    5. Wang L,
    6. Brookhart MA
    : Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients. J Am Soc Nephrol 24: 1461–1469, 2013pmid:23744885
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Arneson TJ,
    2. Li S,
    3. Liu J,
    4. Kilpatrick RD,
    5. Newsome BB,
    6. St Peter WL
    : Trends in hip fracture rates in US hemodialysis patients, 1993-2010. Am J Kidney Dis 62: 747–754, 2013
    OpenUrlCrossRefPubMed
  15. ↵
    1. Gibrat C,
    2. Bousquet M,
    3. Saint-Pierre M,
    4. Lévesque D,
    5. Calon F,
    6. Rouillard C,
    7. Cicchetti F
    : Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry 34: 193–203, 2010pmid:19913065
    OpenUrlCrossRefPubMed
  16. ↵
    1. Chertow GM,
    2. Correa-Rotter R,
    3. Block GA,
    4. Drueke TB,
    5. Floege J,
    6. Goodman WG,
    7. Herzog CA,
    8. Kubo Y,
    9. London GM,
    10. Mahaffey KW,
    11. Mix TC,
    12. Moe SM,
    13. Wheeler DC,
    14. Parfrey PS
    : Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transplant 27: 2872–2879, 2012
    OpenUrlCrossRefPubMed
  17. ↵
    1. Chertow GM,
    2. Pupim LB,
    3. Block GA,
    4. Correa-Rotter R,
    5. Drueke TB,
    6. Floege J,
    7. Goodman WG,
    8. London GM,
    9. Mahaffey KW,
    10. Moe SM,
    11. Wheeler DC,
    12. Albizem M,
    13. Olson K,
    14. Klassen P,
    15. Parfrey P
    : Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and design overview. Clin J Am Soc Nephrol 2: 898–905, 2007pmid:17702710
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Chertow GM,
    2. Block GA,
    3. Correa-Rotter R,
    4. Drueke TB,
    5. Floege J,
    6. Goodman WG,
    7. Herzog CA,
    8. Kubo Y,
    9. London GM,
    10. Mahaffey KW,
    11. Mix CH,
    12. Moe SM,
    13. Trotman ML,
    14. Wheeler DC,
    15. Parfrey PS
    : A randomized trial of cinacalcet in patients on hemodialysis with secondary hyperparathyroidism. N Engl J Med 367: 2482–2494 2012
    OpenUrlCrossRefPubMed
  19. ↵
    1. Parfrey PS,
    2. Chertow GM,
    3. Block GA,
    4. Correa-Rotter R,
    5. Drüeke TB,
    6. Floege J,
    7. Herzog CA,
    8. London GM,
    9. Mahaffey KW,
    10. Moe SM,
    11. Wheeler DC,
    12. Dehmel B,
    13. Trotman ML,
    14. Modafferi DM,
    15. Goodman WG
    : The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial. J Clin Endocrinol Metab 98: 4834–4844, 2013pmid:24108314
    OpenUrlCrossRefPubMed
  20. ↵
    1. Chertow GM,
    2. Parfrey PS
    : Cinacalcet for cardiovascular disease in patients undergoing dialysis. N Engl J Med 368: 1844–1845, 2013pmid:23656653
    OpenUrlPubMed
  21. ↵
    1. Nevitt MC,
    2. Ettinger B,
    3. Black DM,
    4. Stone K,
    5. Jamal SA,
    6. Ensrud K,
    7. Segal M,
    8. Genant HK,
    9. Cummings SR
    : The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Intern Med 128: 793–800, 1998pmid:9599190
    OpenUrlCrossRefPubMed
  22. ↵
    1. Atsumi K,
    2. Kushida K,
    3. Yamazaki K,
    4. Shimizu S,
    5. Ohmura A,
    6. Inoue T
    : Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33: 287–293, 1999
    OpenUrlCrossRefPubMed
  23. ↵
    1. Mares J,
    2. Ohlidalova K,
    3. Opatrna S,
    4. Ferda J
    : Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients. J Bone Miner Metab 27: 217–223, 2009pmid:19172222
    OpenUrlCrossRefPubMed
  24. ↵
    1. Villella VR,
    2. Esposito S,
    3. Maiuri MC,
    4. Raia V,
    5. Kroemer G,
    6. Maiuri L
    : Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR. Autophagy 9: 1431–1434, 2013pmid:23800975
    OpenUrlCrossRefPubMed
  25. ↵
    1. Coco M,
    2. Rush H
    : Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 1115–1121, 2000
    OpenUrlCrossRefPubMed
  26. ↵
    1. Danese MD,
    2. Kim J,
    3. Doan QV,
    4. Dylan M,
    5. Griffiths R,
    6. Chertow GM
    : PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47: 149–156, 2006
    OpenUrlCrossRefPubMed
  27. ↵
    1. Rudser KD,
    2. de Boer IH,
    3. Dooley A,
    4. Young B,
    5. Kestenbaum B
    : Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18: 2401–2407, 2007pmid:17634437
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Garrett G,
    2. Sardiwal S,
    3. Lamb EJ,
    4. Goldsmith DJ
    : PTH—a particularly tricky hormone: Why measure it at all in kidney patients? Clin J Am Soc Nephrol 8: 299–312, 2013pmid:22403273
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Sprague SM,
    2. Moe SM
    : Rebuttal: PTH—a particularly tricky hormone: Why measure it at all in kidney patients? Clin J Am Soc Nephrol 8: 321, 2013pmid:23160258
    OpenUrlFREE Full Text
  30. ↵
    1. Block GA,
    2. Klassen PS,
    3. Lazarus JM,
    4. Ofsthun N,
    5. Lowrie EG,
    6. Chertow GM
    : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218, 2004pmid:15284307
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Stehman-Breen CO,
    2. Sherrard DJ,
    3. Alem AM,
    4. Gillen DL,
    5. Heckbert SR,
    6. Wong CS,
    7. Ball A,
    8. Weiss NS
    : Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58: 2200–2205, 2000pmid:11044242
    OpenUrlCrossRefPubMed
  32. ↵
    1. Mitterbauer C,
    2. Kramar R,
    3. Oberbauer R
    : Age and sex are sufficient for predicting fractures occurring within 1 year of hemodialysis treatment. Bone 40: 516–521, 2007pmid:17070128
    OpenUrlCrossRefPubMed
  33. ↵
    1. Goldsmith D,
    2. Kothawala P,
    3. Chalian A,
    4. Bernal M,
    5. Robbins S,
    6. Covic A
    : Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. Am J Kidney Dis 53: 1002–1013, 2009
    OpenUrlCrossRefPubMed
  34. ↵
    1. Block GA,
    2. Martin KJ,
    3. de Francisco AL,
    4. Turner SA,
    5. Avram MM,
    6. Suranyi MG,
    7. Hercz G,
    8. Cunningham J,
    9. Abu-Alfa AK,
    10. Messa P,
    11. Coyne DW,
    12. Locatelli F,
    13. Cohen RM,
    14. Evenepoel P,
    15. Moe SM,
    16. Fournier A,
    17. Braun J,
    18. McCary LC,
    19. Zani VJ,
    20. Olson KA,
    21. Drüeke TB,
    22. Goodman WG
    : Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525, 2004pmid:15071126
    OpenUrlCrossRefPubMed
  35. ↵
    1. Parfitt AM
    : The hyperparathyroidism of chronic renal failure: A disorder of growth. Kidney Int 52: 3–9, 1997pmid:9211340
    OpenUrlCrossRefPubMed
  36. ↵
    1. Parfitt AM
    : Misconceptions (2): Turnover is always higher in cancellous than in cortical bone. Bone 30: 807–809, 2002pmid:12052445
    OpenUrlCrossRefPubMed
  37. ↵
    1. Leonard MB
    : A structural approach to skeletal fragility in chronic kidney disease. Semin Nephrol 29: 133–143, 2009pmid:19371804
    OpenUrlCrossRefPubMed
  38. ↵
    1. Jamal SA,
    2. Gilbert J,
    3. Gordon C,
    4. Bauer DC
    : Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21: 543–548, 2006
    OpenUrlCrossRefPubMed
  39. ↵
    1. Yajima A,
    2. Ogawa Y,
    3. Takahashi HE,
    4. Tominaga Y,
    5. Inou T,
    6. Otsubo O
    : Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 42: 729–738, 2003
    OpenUrlCrossRefPubMed
  40. ↵
    1. Yajima A,
    2. Inaba M,
    3. Tominaga Y,
    4. Nishizawa Y,
    5. Ikeda K,
    6. Ito A
    : Increased osteocyte death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism. J Bone Miner Res 25: 2374–2381, 2010
    OpenUrlCrossRefPubMed
  41. ↵
    1. Wada M,
    2. Ishii H,
    3. Furuya Y,
    4. Fox J,
    5. Nemeth EF,
    6. Nagano N
    : NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53: 448–453, 1998pmid:9461105
    OpenUrlCrossRefPubMed
  42. ↵
    1. Allen MR,
    2. Chen NX,
    3. Gattone VH 2nd,
    4. Chen X,
    5. Carr AJ,
    6. LeBlanc P,
    7. Brown D,
    8. Moe SM
    : Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int 24: 1471–1481, 2013
    OpenUrlCrossRefPubMed
  43. ↵
    1. Iwasaki Y,
    2. Kazama JJ,
    3. Yamato H,
    4. Fukagawa M
    : Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 48: 1260–1267, 2011pmid:21397740
    OpenUrlCrossRefPubMed
  44. ↵
    1. Tu X,
    2. Rhee Y,
    3. Condon KW,
    4. Bivi N,
    5. Allen MR,
    6. Dwyer D,
    7. Stolina M,
    8. Turner CH,
    9. Robling AG,
    10. Plotkin LI,
    11. Bellido T
    : Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 50: 209–217, 2012pmid:22075208
    OpenUrlCrossRefPubMed
  45. ↵
    1. Takahashi T
    : Overexpression of Runx2 and MKP-1 stimulates transdifferentiation of 3T3-L1 preadipocytes into bone-forming osteoblasts in vitro. Calcif Tissue Int 88: 336–347, 2011pmid:21258786
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 26 (6)
Journal of the American Society of Nephrology
Vol. 26, Issue 6
June 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
Sharon M. Moe, Safa Abdalla, Glenn M. Chertow, Patrick S. Parfrey, Geoffrey A. Block, Ricardo Correa-Rotter, Jürgen Floege, Charles A. Herzog, Gerard M. London, Kenneth W. Mahaffey, David C. Wheeler, Bastian Dehmel, William G. Goodman, Tilman B. Drüeke
JASN Jun 2015, 26 (6) 1466-1475; DOI: 10.1681/ASN.2014040414

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
Sharon M. Moe, Safa Abdalla, Glenn M. Chertow, Patrick S. Parfrey, Geoffrey A. Block, Ricardo Correa-Rotter, Jürgen Floege, Charles A. Herzog, Gerard M. London, Kenneth W. Mahaffey, David C. Wheeler, Bastian Dehmel, William G. Goodman, Tilman B. Drüeke
JASN Jun 2015, 26 (6) 1466-1475; DOI: 10.1681/ASN.2014040414
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Concise Methods
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Kidney Biopsy Features Most Predictive of Clinical Outcomes in the Spectrum of Minimal Change Disease and Focal Segmental Glomerulosclerosis
  • Molecular Characterization of Membranous Nephropathy
  • Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study
Show more Clinical Research

Cited By...

  • Extreme scoliosis from CKD-MBD resulting in respiratory failure and death
  • Management of Osteoporosis in CKD
  • Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis
  • Fractures in Patients with CKD: Time for Action
  • Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis
  • Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis
  • Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Keywords

  • CKD
  • hemodialysis
  • hyperparathyroidism
  • renal
  • osteodystrophy

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire